Expression of MAGE and BAGE genes in Japanese breast cancers

Annals of Oncology

Volumn 8, Issue 4, 1997, Pages 369-372

  Fujie, T ^a   Mori, M ^a   Ueo, H ^b   Sugimachi, K ^c   Akiyoshi, T ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OITA PREFECTURAL HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

BAGE; MAGE; Specific immunotherapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

ARTICLE; BAGE GENE; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAGE GENE; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; AZACITIDINE; BREAST NEOPLASMS; DNA MODIFICATION METHYLASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JAPAN; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 0030966606     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008255630202     Document Type: Article

References (21)

1. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
2. Boël P, Wildmann C, Sensi M et al. BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2: 167-75.
3. Weynants P, Lethé B, Brasseur F et al. Expression of MAGE genes by non-small cell lung carcinomas. Int J Cancer 1994; 56: 826-9.
4. Brasseur F, Marchand M, Vanwijck R et al. Human gene MAGE-1. which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer 1992; 52: 839-41.
5. Patard JJ, Brasseur F, Gil-diez S et al. Expression of MAGE genes in transitional carcinomas of the urinary bladder. Int J Cancer 1995; 64: 60-4.
6. Inoue H, Li J, Honda M et al. MAGE-1 mRNA expression in gastric carcinoma. Int J Cancer 1995; 64: 76-7.
7. Inoue H, Mori M, Li J et al. Human esophageal carcinomas frequently express the tumor rejection antigens of MAGE genes. Int J Cancer 1995; 63: 523-6.
8. Mori M, Inoue H, Mimori K et al. Expression of MAGE genes in human colorectal carcinoma. Ann Surg 1996; 224: 183-8.
9. Weber J, Salgaller M, Samid D et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethlating agent 5-aza-2′-deoxycytidine. Cancer Res 1994; 54: 1766-71.
10. Mori M, Mimori K, Inoue H et al. Detection of cancer micrometastases in lymph nodes by the reverse transcriptase-polymerase chain reaction. Cancer Res 1995; 55: 3417-20.
11. Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921-30.
12. Traversari C, van der Bruggen P, Luscher I et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolyticT lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 1453-7.
13. van der Bruggen P, Szikora JP, Boël P et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanoma expressing HLA-Cw* 1601. Europ J Immunol 1994; 24: 2134-40.
14. van der Bruggen P, Bastin J, Gajewski T et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 12: 3038-44.
15. Coulie PG, Weynants P, Lehmann F et al. Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. J Immunother 1993; 14: 104-9.
16. Russo V, Traversari C, Verrecchia A et al. Expression of the MAGE gene family in primary and metastatic human breast cancer: Implication for tumor antigen-specific immunotherapy. Int J Cancer 1995; 64: 216-21.
17. Herman J, van der Bruggen P, Luesher IF et al. A peptide encoded by human gene MAGE-3 and presented by HLA-B44 induces cytolytic lymphocytes that recognize tumor cell expressing MAGE-3. Immunogenetics (in press).
18. Dong R, Kimura A, Okubo R et al. HLA-A and DPBI loci confer susceptibility to Graves' disease. Hum Immunol 1992; 35: 165-72.
19. van Groeningen CJ, Leyva A, O'brien A et al. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 1986; 46: 4831-6.
20. Rivard GE, Momparler RL, Demers J et al. Phase I study of 5-aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res 1981; 5: 453-62.
21. Zagonel V, Lore G, Marotta G et al. 5-Aza-2′-deoxycytidine (decitabine) is an effective agent for the treatment of advanced myelodysplastic symdromes (MDS). Proc Am Soc Clin Oncol 1992; 858.